Recruiting
Phase 1

Tilrekimig with rHuPH20

Sponsor:

Pfizer

Code:

NCT07792941

Conditions

Healthy

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

tilrekimig and rHuPH20

Study Details

Brief summary:

This study aims to learn how the body handles tilrekimig when given with another medicine called recombinant human hyaluronidase PH20 (rHuPH20). rHuPH20 is approved to help some medicines be taken up by the body when they are given together as an injection (shot) under the skin.

Conditions

Healthy

Study ID

NCT07792941

Start date

Aug 27, 2026

Status verified date

Sep, 2026

Completion date

Feb 11, 2027

Anticipated

Primary completion date

Feb 11, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

  • BMI of 16-32 kg/m2; and a total body weight >50 kg (110 lb).
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. Participants should be able to understand and sign informed consent

Exclusion Criteria:

  • Evidence or history of clinically significant any medical condition
  • History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb or HCVAb.
  • Evidence of active, latent, or inadequately treated infection with Mycobacterium TB
  • History of allergic or anaphylactic reaction with any biologic agents.

Study Design

Enrollment

12 participants

Anticipated

Intervention Model

Single group

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: tilrekimig and rHuPH20

a single dose of co-mixed tilrekimig and rHuPH20

Interventions

tilrekimig and rHuPH20

subcutaneous injection

Primary outcome measure

  • Tilrekimig area under the serum concentration-time curve from time zero to infinity (AUCinf) [ Time Frame: pre-dose, hours 12, 24, 48, 72, and 96 hours post dose. Days 8, 15, 30, 45, 60, 90, 120, and 150 post -dose ]
  • Tilrekimig Maximum Observed Plasma Concentration (Cmax) [ Time Frame: pre-dose, hours 12, 24, 48, 72, and 96 hours post dose. Days 8, 15, 30, 45, 60, 90, 120, and 150 post dose ]

Central Contacts and Locations

Central contacts

Pfizer CT.gov Call Center

1-800-718-1021ClinicalTrials.gov_Inquiries@pfizer.com

Locations

New Haven Pfizer Clinical Research Unit (NH PCRU)

Recruiting

New Haven, Connecticut, United States, 06511

More Information

Sponsor

Pfizer

Last update posted

Sep 4, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Pfizer on 2026-09-04.